Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2007

View Archived Issues

HDL mimetic CSL-111 shown to reduce atherosclerotic burden in the ERASE trial

Valortim demonstrates therapeutic effect in new primate model of anthrax

Plant-derived vaccine adjuvant shows enhanced immune response against hepatitis B in mice

Avanir provides business update

Phase II study of incyclinide in acne studies 40 mg dose

PRX-00023 studied in new phase IIb trial for major depressive disorder

FDA requires additional phase III study for cintredekin besudotox

Phase I/II data for Baxter's adjuvant-free pandemic H5N1 influenza vaccine

Hollis-Eden files IND to begin clinical testing of HE-3286 for metabolic disorders

European orphan drug status for Elafin

Udenafil demonstrates efficacy in erectile dysfunction phase IIb study

Structure and biological evaluation of CKD-501 presented at the ACS meeting

Novel glucocorticoid receptor modulator profiled at Merck

Provenge recommended for approval for prostate cancer

New data presented for bifeprunox

CanBas and Takeda collaborate in cancer

Aska licenses rights to JCR's recombinant FSH

PC-190708: a novel DNA gyrase B inhibitor identified at Prolysis

New agents for treating extrapyramidal disorders disclosed in recent Kissei patents

Recent patents report novel therapeutic agents for metabolic disorders

Recent Pfizer patent discloses new treatments for attention deficit hyperactivity disorder

Ceprotin approved for severe congenital protein C deficiency

Novartis suspends U.S. sales of Zelnorm

Janumet receives FDA approval

Lapatinib filed for approval in Japan for advanced breast cancer

Abbott seeks U.S. and E.U. approval of Humira for chronic plaque psoriasis

Twinrix approved for new accelerated dosing schedule

Exjade filed in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...